Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Tine Thurison Soerensen, PhD

    TitlePostdoctoral Scholar
    SchoolUCSF School of Pharmacy
    DepartmentPharmaceutical Chemistry
    Address600 16th Street
    San Francisco CA 94158
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      University of California San FranciscoPost docPharm Chem, Craik Lab2015
      University of CopenhagenPost docThe Finsen Laboratory/BRIC, Ploug Lab2015
      University of CopenhagenPh.DFaculty of Health Sciences2014
      Copenhagen University HospitalResearch assistantThe Finsen Laboratory, Hoyer-Hansen Lab2010
      University of CopenhagenM.Sc.Faculty of Health Sciences2009
      Collapse Awards and Honors
      The Danish Cancer Society2012 - 2014Independent Junior Research Grant

      Collapse ORNG Applications 
      Collapse Websites
      Collapse Featured Publications

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Thurison T, Almholt K, Gårdsvoll H, Ploug M, Høyer-Hansen G, Lund IK. Urokinase receptor cleavage correlates with tumor volume in a transgenic mouse model of breast cancer. Mol Carcinog. 2016 May; 55(5):717-31. PMID: 25809119.
        View in: PubMed
      2. Thurison T, Christensen IJ, Lund IK, Nielsen HJ, Høyer-Hansen G. Circulating intact and cleaved forms of the urokinase-type plasminogen activator receptor: biological variation, reference intervals and clinical useful cut-points. Clin Chim Acta. 2015 Jan 15; 439:84-90. PMID: 25305537.
        View in: PubMed
      3. Illemann M, Laerum OD, Hasselby JP, Thurison T, Høyer-Hansen G, Nielsen HJ, Christensen IJ. Urokinase-type plasminogen activator receptor (uPAR) on tumor-associated macrophages is a marker of poor prognosis in colorectal cancer. Cancer Med. 2014 Aug; 3(4):855-64. PMID: 24889870; PMCID: PMC4303153.
      4. Grunnet M, Christensen IJ, Lassen U, Jensen LH, Lydolph M, Lund IK, Thurison T, Høyer-Hansen G, Mau-Sørensen M. Prognostic significance of circulating intact and cleaved forms of urokinase plasminogen activator receptor in inoperable chemotherapy treated cholangiocarcinoma patients. Clin Biochem. 2014 May; 47(7-8):599-604. PMID: 24530340.
        View in: PubMed
      5. Lund IK, Illemann M, Thurison T, Christensen IJ, Høyer-Hansen G. uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy. Curr Drug Targets. 2011 Nov; 12(12):1744-60. PMID: 21707477.
        View in: PubMed
      6. Thurison T, Lomholt AF, Rasch MG, Lund IK, Nielsen HJ, Christensen IJ, Høyer-Hansen G. A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer. Clin Chem. 2010 Oct; 56(10):1636-40. PMID: 20802096.
        View in: PubMed
      7. Olson FJ, Thurison T, Ryndel M, Høyer-Hansen G, Fagerberg B. Soluble urokinase-type plasminogen activator receptor forms in plasma as markers of atherosclerotic plaque vulnerability. Clin Biochem. 2010 Jan; 43(1-2):124-30. PMID: 19822140.
        View in: PubMed
      Tine Thurison's Networks
      Related Concepts
      Derived automatically from this person's publications.
      Related Authors
      People who share related concepts with this person.
      Back to TOP